Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASA-2
- Development stage
- Preclinical
- Lead developer
- Adjuvax
- Modality
- Small Molecules
- Administration
- Intramuscular, Intranasal, Oral, Subcutaneous
01
Overview
ASA-2 is a natural saponin-based vaccine adjuvant developed by Adjuvax for veterinary applications. Derived from natural sources, ASA-2 is designed to enhance both systemic and mucosal immune responses when formulated into veterinary vaccines. Unlike synthetic or semi-synthetic alternatives, ASA-2 is a naturally occurring saponin component. It is currently in preclinical development as part of ASA-adjuvanted systemic and mucosal veterinary vaccine formulations, serving as a potent immunostimulant to boost vaccine efficacy.
- Other names
- ASA-2 adjuvantASA2 adjuvantASA 2 adjuvant
Beyond the preview
Go deeper on ASA-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASA-2.